

**FORM 51-102F3
MATERIAL CHANGE REPORT**

1. NAME AND ADDRESS OF COMPANY

Eastwood Bio-Medical Canada Inc.
1130 - 4871 Shell Road
Richmond, British Columbia
V6X 3Z6

2. DATE OF MATERIAL CHANGE

September 26, 2017

3. NEWS RELEASE

News release dated September 26, 2017 was disseminated through the facilities of Stockwatch and Market News Publishing Inc.

4. SUMMARY OF MATERIAL CHANGE

Eastwood Bio-Medical Canada Inc. (the “**Company**”) announced that it completed a non-brokered private placement for gross proceeds of \$99,450.

5. FULL DESCRIPTION OF MATERIAL CHANGE

The Company announced that it completed its previously announced non-brokered private placement. The private placement consisted of 1,530,000 common shares at a price of \$0.065 per share for gross proceeds of \$99,450.

The proceeds from the private placement will be used for general working capital. The securities issued pursuant to the private placement are subject to a four month hold period expiring on January 27, 2018.

The Private Placement was subscribed for by Dr. Youngsoo Kim, a director of the Company’s major shareholder, Eastwood Bio-Medical Research Inc. (“EBMR”). The Private Placement with Dr. Kim constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 *Protection of Minority Security Holders in Special Transactions* (“MI 61-101”). The Company is relying on the exemptions from the formal valuation and minority approval requirements contained in Sections 5.5(a) and 5.7(1)(a) of MI 61-101 on the basis that the fair market value of the transaction does not exceed 25% of the Company’s market capitalization.

6. RELIANCE ON SUBSECTION 7.1(2) OF NATIONAL INSTRUMENT 51-102

Not applicable.

7. **OMITTED INFORMATION**

Not applicable.

8. **EXECUTIVE OFFICER**

Yunji Kim
President and Chief Executive Officer
Telephone: (604) 247-2100

9. **DATE OF REPORT**

October 2, 2017